Integrative therapy for cannabis misuse in adolescents
Assessment of the Effectiveness of an Integrative Therapy for Cannabis Misuse in Adolescents (Randomized Controlled Trial of Non-inferiority)
This study is testing a new therapy that combines different counseling techniques to see if it can help teenagers in France reduce their cannabis use and improve their mental health and relationships.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 14 Years to 20 Years |
| Sex | All |
| Sponsor | Centre Hospitalier St Anne Academic / other |
| Locations | 1 site (Paris) |
| Trial ID | NCT05765409 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of an Integrative Therapy for Adolescent Cannabis Use (TIMCA), which combines Motivational Interviewing (MI), Cognitive Behavioral Therapies (CBT), and an Attachment-Based Intervention (ABI). The TIMCA will be compared to Treatment As Usual (TAU) to assess its impact on cannabis use and related psychological factors. Secondary objectives include evaluating improvements in relationship quality with parents and friends, emotional regulation strategies, and symptoms of depression and anxiety. The study aims to address the significant public health issue of cannabis use among adolescents, particularly in France.
Who should consider this trial
Good fit: Ideal candidates are adolescents aged 14 to 19 years with a diagnosis of Cannabis Use Disorder who are fluent in French.
Not a fit: Patients with acute psychiatric disorders, other substance use disorders, or those already engaged in therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly reduce cannabis use and improve emotional and relational well-being in adolescents.
How similar studies have performed: Previous studies have shown that combining MI and CBT is effective for young cannabis users, suggesting potential success for this integrative approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged 14 to 19 years 11 months 29 (or 30) days at the time of the inclusion visit * Consulting as an outpatient center: * Fulfilling the criteria for Cannabis Use Disorder (CUD) according to DSM 5 criteria (mild, moderate or severe) * Fluent in oral and written French * Benefiting from a social security plan * Having signed their consent to participate (and their legal representative if applicable). Exclusion Criteria: * With an acute psychiatric disorder and/or a psychotropic treatment (a characterized depressive episode, a bipolar disorder, a psychotic disorder) * With a substance use disorder other than cannabis and tobacco, * Already engaged in another form of therapy * Pregnant women at the time of inclusion * Participants of age subject to a legal protection measure or unable to express their consent
Where this trial is running
Paris
- GHU Paris Psychiatrie & Neurosciences — Paris, France (Recruiting)
Study contacts
- Principal investigator: Hassan Rahioui, Doctor — GHU Paris Psychiatry & Neurosciences
- Study coordinator: Yara BOU NASSIF, psychologist
- Email: y.bou_nassif@ghu-paris.fr
- Phone: 0630707681
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.